Becapio
4 employees on LinkedIn · 1 known investors
Find your way into Becapio
211 people in our graph share verified history with the Becapio team — schools, employers, funds. One of them is your warm intro.
BeCapio develops a non-invasive medical device system to treat fecal incontinence (accidental bowel leakage), combining electrical stimulation of the anal sphincters and pelvic muscles with a sealing plug for immediate leak prevention. The device is in the research and development stage and is being developed in cooperation with Sha'are Zedek Medical Center.
Also known as BeCapio
Founders & leadership
Board
Investors · 1
Company profile
researched Aug 2026BeCapio is a medical device company developing a non-invasive system intended to address fecal incontinence (accidental bowel leakage). The company frames the condition as a chronic, debilitating problem affecting quality of life, citing that 10% of middle-aged adults experience frequent fecal incontinence.
The system combines two components. A small reusable control unit generates electrical pulses, delivered both on demand and continuously, to stimulate the anal sphincters and pelvic muscles; it offers a user interface for prompt activation, a Bluetooth connection allowing a health provider to configure maximum tolerable intensity and stimulation duration per patient, and measurement of EMG and impedance signals to quantify squeezing improvement over time and provide training feedback for future patient-customization applications. A disposable anal patch carries skin electrodes positioned around the anus and a soft silicone plug backed by a rigid skeleton that provides external sealing, with a multi-layer ergonomic design for skin attachment and detachment. The stated combined approach targets immediate leak prevention, on-demand muscle reinforcement, improvement over time, and wellness support.
The device is described by the company as being in the research and development phase and not evaluated or approved for sale. Development is carried out in cooperation with Sha'are Zedek Medical Center, and the company states it is led by a team of experts in the medical device field.
Traction
A full-system clinical trial is described as enrolling. The company reports preliminary clinical and usability data indicating the patch is convenient to wear and gives a feeling of protection and security. The device has not been evaluated or approved for sale.
Latest developments
A clinical trial of the full system is open for enrollment, with an inquiry form on the company website for prospective participants.
▸Full profile — market position, technology, go-to-market, geography
Market position
An early-stage, pre-approval developer in the fecal incontinence treatment space, addressing a condition the company describes as affecting 10% of middle-aged adults frequently.
The company positions its approach as combining, in a single non-invasive system, immediate mechanical leak prevention via a sealing plug with electrical stimulation for on-demand muscle reinforcement and improvement over time, rather than addressing a single factor of a multi-factorial condition.
Technology
The system pairs a reusable electrical stimulation control unit with a disposable anal patch. The control unit generates on-demand and continuous electrical pulses to stimulate anal sphincter and pelvic muscles, connects over Bluetooth so a clinician can set maximum tolerable stimulation intensity and duration for each patient, and measures EMG and impedance signals to quantify squeezing improvement and provide training feedback. The patch positions skin electrodes around the anus and incorporates a soft silicone plug with a rigid internal skeleton to provide external sealing, using a layered ergonomic construction intended to ease application and removal.
Go-to-market
Adults affected by fecal incontinence (accidental bowel leakage), a condition the company states occurs frequently in 10% of middle-aged adults; device configuration parameters such as maximum tolerable intensity and stimulation duration are set by a health provider, indicating clinician involvement in patient care.
Geography
Based in Israel, with contact address at T'chelet 17, Misgav Business Park, Israel 2017400, and development conducted in cooperation with Sha'are Zedek Medical Center.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsBeCapio states that a clinical trial of its full system is now enrolling participants.
The device is being developed in cooperation with Sha'are Zedek Medical Center.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 7
primary sources listed
- Becapiobecapio.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Becapio do?
- Israeli medical device developer of a non-invasive system for treating fecal incontinence.
- Who founded Becapio?
- Becapio was founded by Dan Livovsky, Joseph Lysy.
- Who are Becapio's investors?
- Becapio's investors include Trendlines Group.